– Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 17, 2018--
Inc. (Nasdaq: EXEL) announced today that its second quarter 2018
financial results will be released on Wednesday, August 1, 2018 after
the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management
will host a conference call and webcast to discuss the results and
provide a general business update. Access to the event is available via
the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the conference call to ensure adequate time
for any software download that may be required to listen to the webcast.
Alternatively, please call 855-793-2457 (domestic) or 631-485-4921
(international) and provide the conference call passcode 5668207 to join
A telephone replay will be available until 8:30 p.m. EDT on August 3,
2018. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is 5668207. A
webcast replay will also be archived on www.exelixis.com
for one year.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our three
commercially available products, CABOMETYX® (cabozantinib),
COMETRIQ® (cabozantinib) and COTELLIC®
(cobimetinib), and have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to patients
worldwide. Supported by revenues from our marketed products and
collaborations, we are committed to prudently reinvesting in our
business to maximize the potential of our pipeline. We are supplementing
our existing therapeutic assets with targeted business development
activities and internal drug discovery – all to deliver the next
generation of Exelixis medicines and help patients recover stronger and
live longer. In July 2018, Exelixis was added to the Standard & Poor’s
(S&P) MidCap 400 index, which measures the performance of profitable
mid-sized companies. For more information about Exelixis, please visit www.exelixis.com,
on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180717005966/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
Public Affairs & Investor Relations